MedTrace Logo

CerebrAlcare Pills on CereBral Small VesseL DiseasE（CABLE）

NCT05578521 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2022-10-13

No results posted yet for this study

Summary

This is a randomized, double-blinded, placebo-controlled, multicenter trial. Cerebral small vessel disease (CSVD) patients will be diagnosed by Magnetic Resonance Imaging (MRI) and randomized into treatment or control groups. The purpose of this trial is to assess the efficacy of cerebralcare pills on cerebral small vessel disease.

Conditions

  • Cerebral Small Vessel Diseases

Interventions

DRUG

Cerebralcare pills

a dose of 2 packages, twice a day of Cerebralcare pills

DRUG

Cerebralcare pills placebo

Cerebralcare pills placebo will be administrated at the same rate with experimental group

Sponsors & Collaborators

  • Tasly Pharmaceutical Group Co., Ltd

    collaborator INDUSTRY

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Yilong Wang, PhD，MD · Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-05
Primary Completion
2023-12-31
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05578521 on ClinicalTrials.gov